|
Hodgkin Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Ibrutinib, an oral inhibitor of Bruton's tyrosine kinase, has altered the treatment perspective of chronic lymphocytic leukemia and showed modest activity against several types of non-Hodgkin's lymphomas.
|
31142233 |
2020 |
|
Hematologic Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Ibrutinib is an oral inhibitor of Bruton's tyrosine kinase that is used for a variety of B cell hematological malignancies.
|
31216242 |
2020 |
|
Rheumatoid Arthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Fenebrutinib (GDC-0853) is an orally administered small molecule inhibitor of Bruton's tyrosine kinase being investigated for treatment of rheumatoid arthritis in patients with inadequate responses to methotrexate (MTX).
|
31371481 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.010 |
Biomarker
|
disease |
BEFREE |
Ibrutinib, an inhibitor of Bruton tyrosine kinase (BTK), has shown promising pharmacologic effects in acute myeloid leukemia (AML).
|
31310800 |
2019 |
|
Lymphoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Here, we report that loss of the murine Ibtk gene raises survival and delays tumor onset in Eμ-myc transgenic mice, a preclinical model of Myc-driven lymphoma.
|
30975981 |
2019 |
|
Waldenstrom Macroglobulinemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Ibrutinib is an oral covalent inhibitor of Bruton's tyrosine kinase approved for the treatment of patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma and Waldenstrӧm's macroglobulinemia.
|
30785921 |
2019 |
|
Pneumonia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, these data indicate that the Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses during acute pulmonary inflammation evoked by LTA and antibiotic-treated pneumococcal pneumonia and suggest that ibrutinib has the potential to inhibit ongoing lung inflammation in an acute infectious setting.
|
30646846 |
2019 |
|
Lobar Pneumonia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, these data indicate that the Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses during acute pulmonary inflammation evoked by LTA and antibiotic-treated pneumococcal pneumonia and suggest that ibrutinib has the potential to inhibit ongoing lung inflammation in an acute infectious setting.
|
30646846 |
2019 |
|
Streptococcal pneumonia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, these data indicate that the Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses during acute pulmonary inflammation evoked by LTA and antibiotic-treated pneumococcal pneumonia and suggest that ibrutinib has the potential to inhibit ongoing lung inflammation in an acute infectious setting.
|
30646846 |
2019 |
|
Malignant lymphoma - lymphoplasmacytic
|
0.010 |
Biomarker
|
disease |
BEFREE |
Ibrutinib is an oral covalent inhibitor of Bruton's tyrosine kinase approved for the treatment of patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma and Waldenstrӧm's macroglobulinemia.
|
30785921 |
2019 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
However, the role of IBTK in tumorigenesis has not been elucidated.
|
30975981 |
2019 |
|
Leukemogenesis
|
0.010 |
Biomarker
|
disease |
BEFREE |
IBTK contributes to B-cell lymphomagenesis in Eμ-myc transgenic mice conferring resistance to apoptosis.
|
30975981 |
2019 |
|
Waldenstrom's disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Ibrutinib is an oral inhibitor of Bruton tyrosine kinase approved for the treatment of chronic lymphocytic leukaemia, mantle cell lymphoma and refractory Waldenstrom's disease.
|
31287200 |
2019 |
|
Adult Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we report that loss of the murine Ibtk gene raises survival and delays tumor onset in Eμ-myc transgenic mice, a preclinical model of Myc-driven lymphoma.
|
30975981 |
2019 |
|
Childhood Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we report that loss of the murine Ibtk gene raises survival and delays tumor onset in Eμ-myc transgenic mice, a preclinical model of Myc-driven lymphoma.
|
30975981 |
2019 |
|
Pneumonitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, these data indicate that the Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses during acute pulmonary inflammation evoked by LTA and antibiotic-treated pneumococcal pneumonia and suggest that ibrutinib has the potential to inhibit ongoing lung inflammation in an acute infectious setting.
|
30646846 |
2019 |
|
Brain Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
We used a novel inhibitor of Bruton's tyrosine kinase (BTK), BI-BTK-1, to target both macrophage and B cell function in the MRL-lpr/lpr murine model of SLE, and examined the effect of treatment on skin and brain disease.
|
29370834 |
2018 |
|
Multiple Myeloma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Ibrutinib (also referred to as PCI-32765), an inhibitor of Bruton's tyrosine kinase, while its effects on multiple myeloma have not been well described.
|
29320977 |
2018 |
|
Mantle cell lymphoma refractory
|
0.010 |
Biomarker
|
disease |
BEFREE |
Targeted agents such as ibrutinib, an inhibitor of Bruton's tyrosine kinase, which has been approved only in the relapsed setting, can be used to treat patients with relapsed or refractory mantle cell lymphoma.
|
29907126 |
2018 |
|
leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Ibrutinib (Imbruvica<sup>®</sup>) is an oral irreversible inhibitor of Bruton's tyrosine kinase, a B-cell receptor (BCR) signalling kinase expressed by various haematopoietic cells, B-cell lymphomas and leukaemias.
|
28105602 |
2017 |
|
Primary central nervous system lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b/> In this issue Grommes and colleagues elegantly show that the irreversible inhibitor of Bruton tyrosine kinase, ibrutinib, promotes a high proportion of durable responses in primary central nervous system lymphoma, a type of diffuse large B-cell lymphoma (DLBCL), and also in secondary DLBCL relapsing to the central nervous system.
|
28864640 |
2017 |
|
Nonalcoholic Steatohepatitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Function of inhibitor of Bruton's tyrosine kinase isoform α (IBTKα) in nonalcoholic steatohepatitis links autophagy and the unfolded protein response.
|
28710282 |
2017 |
|
Nephroblastoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
For example, the IBtK protein and the SH2 domain-containing protein were present in siRNA(WT1) conditions, while the platelet-derived growth factor receptor α (PDGFRA) and Rho guanine nucleotide exchange factor 1 (Rho-GEF 1) were expressed in siRNA(neg).
|
24503937 |
2014 |
|
Chronic lymphocytic leukaemia refractory
|
0.010 |
Biomarker
|
disease |
BEFREE |
At the present time, GS-1101, which reversibly inhibits PI3Kδ, and ibrutinib (PCI-32765), an irreversible inhibitor of Bruton tyrosine kinase, have generated the most promising early results in clinical trials including predominately refractory CLL where durable disease control has been observed.
|
22715122 |
2012 |
|
B-Cell Lymphomas
|
0.020 |
Biomarker
|
group |
BEFREE |
Ibrutinib, an inhibitor of Bruton's tyrosine kinase, and venetoclax, an inhibitor of B-cell lymphoma 2 protein, have been approved for patients with chronic lymphocytic leukemia (CLL).
|
31141631 |
2019 |